Effects of DPP4 Inhibition on COVID-19

Inclusion Criteria: * Type 2 Diabetes Mellitus (T2DM) as per American Diabetes Association (ADA) guidelines * Age ≥ 18 * Confirmed COVID-19 * Mild COVID-19 defined as any of the following: fever, malaise, cough, headache, sore throat, myalgia, nasal congestion, diarrhea * Moderate COVID-19 is defined as \> 2 of the following in non-intubated patients: any symptom of mild disease, radiographic imaging (chest x-ray or lung ultrasound) with bilateral ground glass opacities or bilateral consolidations, SpO2 \<90% up to 5L Nasal Cannula (NC) * No additional signs or symptoms of severe COVID-19. Exclusion Criteria: * Type 1 Diabetes Mellitus (T1DM) diabetes, as per ADA guidelines * History of Diabetic Ketoacidosis (DKA) * History of acute pancreatitis * Chronic or Acute Renal Failure with Estimated Glomerular Filtration Rate (eGFR) \< 30 ml/min/1.73 m2 Exclusion Criteria: T1DM diabetes, as per ADA guidelines, History of DKA, History of acute pancreatitis; Chronic or Acute Renal Failure with eGFR \< 30 ml/min/1.73 m2